Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | PD184352 | 0.1 | uM | IL-17A | 100 | ng/mL | 1 | IFN-g | 24.0 | 57 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 1 | IFN-g | 23.0 | 54 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 1 | IFN-g | 21.5 | 84 | |
N2586 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 1 | IFN-g | 24.5 | 62 | |
N2586 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 1 | IFN-g | 22.0 | 77 | |
RA2159 | 1 | IFN-g | 23.0 | 64 | |||||||
RA2159 | PD184352 | 0.1 | uM | 1 | IFN-g | 21.0 | 61 | ||||
RA2159 | Lestaurtinib | 0.3 | uM | 1 | IFN-g | 22.5 | 68 | ||||
RA2159 | Ruxolitinib | 0.3 | uM | 1 | IFN-g | 21.0 | 57 | ||||
RA2159 | Tofacitinib | 0.3 | uM | 1 | IFN-g | 22.0 | 37 | ||||
RA2159 | IKK16 | 2.0 | uM | 1 | IFN-g | 19.0 | 62 | ||||
RA2159 | JNK-IN-8 | 3.0 | uM | 1 | IFN-g | 22.0 | 64 | ||||
N2586 | 1 | IFN-g | 24.0 | 49 | |||||||
N2586 | PD184352 | 0.1 | uM | 1 | IFN-g | 16.5 | 56 | ||||
N2586 | Lestaurtinib | 0.3 | uM | 1 | IFN-g | 19.0 | 32 | ||||
N2586 | Ruxolitinib | 0.3 | uM | 1 | IFN-g | 20.0 | 40 | ||||
N2586 | Tofacitinib | 0.3 | uM | 1 | IFN-g | 21.5 | 38 | ||||
N2586 | IKK16 | 2.0 | uM | 1 | IFN-g | 25.0 | 53 | ||||
N2586 | JNK-IN-8 | 3.0 | uM | 1 | IFN-g | 21.5 | 56 | ||||
RA2159 | EGF | 100 | ng/mL | 1 | IFN-g | 22.0 | 47 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 1 | IFN-g | 18.0 | 48 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-g | 22.0 | 34 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-g | 28.0 | 53 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-g | 21.0 | 41 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 1 | IFN-g | 21.0 | 57 |